Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Daratumumab as a Treatment for Adult Immune Thrombocytopenia (The DART Study)

NCT04703621 is registered in ClinicalTrials.gov with Ostfold Hospital Trust as lead sponsor.

NCT NCT04703621
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04703621 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Daratumumab as a Treatment for Adult Immune Thrombocytopenia (The DART Study)
Lead sponsor
Ostfold Hospital Trust
Phase
Phase 2
Overall status
Unknown status
Start date
January 21, 2021
Completion date
December 31, 2024
Enrollment
21 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

itp